1. The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy.
- Author
-
Voiosu AM, Bălănescu P, Daha I, Smarandache B, Rădoi A, Mateescu RB, Băicuş CR, and Voiosu TA
- Subjects
- Aged, Biomarkers blood, Cardiomyopathies blood, Cardiomyopathies diagnosis, Cohort Studies, Female, Humans, Liver Cirrhosis blood, Liver Cirrhosis diagnosis, Liver Cirrhosis mortality, Male, Middle Aged, Prognosis, Romania epidemiology, Cardiomyopathies etiology, Liver Cirrhosis complications, Neoplasm Proteins blood, Proteoglycans blood
- Abstract
Background: We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy., Materials and Methods: Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes., Results: 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 vs. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1)., Conclusion: Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population.
- Published
- 2018
- Full Text
- View/download PDF